News
Pharmaceutical company Novo Nordisk (NVO) came out swinging Wednesday morning as the stock initially jumped on its first quarter earnings beat ($0.99 per share vs. estimates of $0.94). Revenue figures ...
The deal could expand access to its in-demand obesity drug at the expense of Eli Lilly, whose shares fell by double digits on ...
The obesity drug price wars are finally starting. After being publicly lambasted for the high cost of their weight-loss shots ...
As Novo Nordisk works through a period of transition in the U.S. GLP-1 drug market, sales from the company's star obesity ...
Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...
Wegovy maker expects second-half rise in business that used to go to pharmacies’ custom-made ‘compounded’ versions ...
Wegovy to become preferred GLP-1 drug on CVS Caremark's top formularies in 2025 as Novo Nordisk expands patient access ...
Novo reported $11.9 billion in revenues, in line with Wall Street's estimates, and beat on adjusted earnings per share (EPS) ...
GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...
Eli Lilly won't lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback